Chimeric Antigen Receptor (CAR)-T cell therapy is a promising development in cancer immunotherapy, but method optimization is necessary to produce the cells at scale. In this two-part webinar, Nucleus Biologics introduces a new resource for improving the CAR-T expansion process.

Brought to you by Nucleus Biologics, the Leader in Precision Cell Culture. For more information, visit [ Ссылка ]

свернуть